

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

UNITED STATES ANTIMONY CORP

Form: 10-Q

Date Filed: 2019-11-14

Corporate Issuer CIK: 101538

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-Q

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period _____ to _____

Commission file number 001-08675

UNITED STATES ANTIMONY CORPORATION
(Exact name of registrant as specified in its charter)

<u>Montana</u> (State or other jurisdiction of incorporation or organization)	<u>81-0305822</u> (I.R.S. Employer Identification No.)
<u>P.O. Box 643, Thompson Falls, Montana</u> (Address of principal executive offices)	<u>59873</u> (Zip code)

Registrant's telephone number, including area code: **(406) 827-3523**

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," "small reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer
Non-Accelerated Filer

Accelerated Filer
Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company as defined by Rule 12b-2 of the Exchange Act. YES No

At November 14, 2019, the registrant had outstanding 69,661,436 shares of par value \$0.01 common stock.

UNITED STATES ANTIMONY CORPORATION
QUARTERLY REPORT ON FORM 10-Q
FOR THE PERIOD
ENDED SEPTEMBER 30, 2019
(UNAUDITED)

TABLE OF CONTENTS

	Page
<u>PART I – FINANCIAL INFORMATION</u>	
<u>Item 1: Financial Statements (unaudited)</u>	<u>1-16</u>
<u>Item 2: Management’s Discussion and Analysis of Results of Operations and Financial Condition</u>	<u>17-21</u>
<u>Item 3: Quantitative and Qualitative Disclosure about Market Risk</u>	<u>22</u>
<u>Item 4: Controls and Procedures</u>	<u>22</u>
<u>PART II – OTHER INFORMATION</u>	
<u>Item 1: Legal Proceedings</u>	<u>23</u>
<u>Item 2: Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>23</u>
<u>Item 3: Defaults upon Senior Securities</u>	<u>23</u>
<u>Item 4: Mine Safety Disclosures</u>	<u>23</u>
<u>Item 5: Other Information</u>	<u>23</u>
<u>Item 6: Exhibits and Reports on Form 8-K</u>	<u>23</u>
<u>SIGNATURE</u>	<u>24</u>
<u>CERTIFICATIONS</u>	<u>25-29</u>

[The balance of this page has been intentionally left blank.]

PART I-FINANCIAL INFORMATION

Item 1. Financial Statements

**United States Antimony Corporation and Subsidiaries
Consolidated Balance Sheets (Unaudited)**

ASSETS

	<u>September 30,</u> <u>2019</u>	<u>December 31,</u> <u>2018</u>
Current assets:		
Cash and cash equivalents	\$ 71,758	\$ 56,650
Certificates of deposit	253,552	252,954
Accounts receivable	322,940	438,391
Inventories	708,074	755,261
Note receivable - sale of land	-	400,000
Total current assets	<u>1,356,324</u>	<u>1,903,256</u>
Properties, plants and equipment, net	15,229,807	15,227,172
Restricted cash for reclamation bonds	57,248	57,247
IVA receivable and other assets	329,947	369,448
Total assets	<u>\$ 16,973,326</u>	<u>\$ 17,557,123</u>

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:		
Checks issued and payable	\$ 31,705	\$ 46,482
Accounts payable	2,060,557	1,926,320
Due to factor	59,104	16,524
Accrued payroll, taxes and interest	200,362	159,037
Other accrued liabilities	401,376	353,911
Payables to related parties	343,263	93,567
Deferred revenue	32,400	32,400
Notes payable to bank	198,228	183,917
Long-term debt, current portion, net of discount	<u>851,766</u>	<u>705,460</u>
Total current liabilities	<u>4,178,761</u>	<u>3,517,618</u>
Long-term debt, net of discount and current portion	876,073	1,027,730
Hillgrove advances payable	1,134,221	1,134,221
Stock payable to directors for services	96,875	175,000
Asset retirement obligations and accrued reclamation costs	<u>282,331</u>	<u>277,720</u>
Total liabilities	<u>6,568,261</u>	<u>6,132,289</u>
Commitments and contingencies (Note 7 an 11)		
Stockholders' equity:		
Preferred stock \$0.01 par value, 10,000,000 shares authorized:		
Series A: -0- shares issued and outstanding	-	-
Series B: 750,000 shares issued and outstanding (liquidation preference \$930,000 and \$922,500 respectively)	7,500	7,500
Series C: 177,904 shares issued and outstanding (liquidation preference \$97,847 both years)	1,779	1,779
Series D: 1,751,005 shares issued and outstanding (liquidation preference \$5,002,470 and \$4,961,324 respectively)	17,509	17,509
Common stock, \$0.01 par value, 90,000,000 shares authorized; 69,661,436 and 68,227,171 shares issued and outstanding, respectively	696,614	682,271
Additional paid-in capital	37,134,853	36,406,874
Accumulated deficit	<u>(27,453,190)</u>	<u>(25,691,099)</u>
Total stockholders' equity	<u>10,405,065</u>	<u>11,424,834</u>
Total liabilities and stockholders' equity	<u>\$ 16,973,326</u>	<u>\$ 17,557,123</u>

The accompanying notes are an integral part of the consolidated financial statements.

	For the three months ended		For the nine months ended	
	September 30, 2019	September 30, 2018	September 30, 2019	September 30, 2018
REVENUES	\$ 1,787,934	\$ 2,091,725	\$ 6,516,582	\$ 6,781,001
COST OF REVENUES	<u>2,058,751</u>	<u>2,268,854</u>	<u>7,029,647</u>	<u>6,871,870</u>
GROSS PROFIT (LOSS)	<u>(270,817)</u>	<u>(177,129)</u>	<u>(513,065)</u>	<u>(90,869)</u>
OPERATING EXPENSES (INCOME):				
General and administrative	139,456	151,825	498,539	489,067
Salaries and benefits	91,178	93,723	424,208	281,596
Professional fees	40,010	211,583	163,204	332,550
Other operating expenses	-	-	86,630	-
Gain on plant acquisition (Note 13)	-	(1,500,000)	-	(1,500,000)
TOTAL OPERATING EXPENSES (INCOME)	<u>270,644</u>	<u>(1,042,869)</u>	<u>1,172,581</u>	<u>(396,787)</u>
INCOME (LOSS) FROM OPERATIONS	<u>(541,461)</u>	<u>865,740</u>	<u>(1,685,646)</u>	<u>305,918</u>
OTHER INCOME (EXPENSE):				
Interest income	19	19	791	849
Gain on tax settlement (Note 11)	-	443,110	-	443,110
Interest expense	(24,444)	(27,516)	(71,160)	(76,163)
Foreign exchange loss	-	(12,752)	-	-
Factoring expense	(2,706)	(1,154)	(6,076)	(3,492)
TOTAL OTHER INCOME (EXPENSE)	<u>(27,131)</u>	<u>401,707</u>	<u>(76,445)</u>	<u>364,304</u>
NET INCOME (LOSS) BEFORE INCOME TAXES	<u>(568,592)</u>	<u>1,267,447</u>	<u>(1,762,091)</u>	<u>670,222</u>
Preferred dividends	<u>(12,162)</u>	<u>(12,162)</u>	<u>(36,487)</u>	<u>(36,487)</u>
Net income (loss) available to common stockholders	<u>\$ (580,754)</u>	<u>\$ 1,255,285</u>	<u>\$ (1,798,578)</u>	<u>\$ 633,735</u>
Net income (loss) per share of common stock:				
Basic	<u>\$ (0.02)</u>	<u>\$ 0.02</u>	<u>\$ (0.01)</u>	<u>\$ 0.01</u>
Diluted	<u>\$ (0.02)</u>	<u>\$ 0.02</u>	<u>\$ (0.01)</u>	<u>\$ 0.01</u>
Weighted average shares outstanding:				
Basic	<u>69,224,297</u>	<u>68,227,171</u>	<u>68,818,050</u>	<u>67,894,207</u>
Diluted	<u>69,224,297</u>	<u>68,373,471</u>	<u>68,818,050</u>	<u>67,992,339</u>

The accompanying notes are an integral part of the consolidated financial statements.

United States Antimony Corporation and Subsidiaries
Consolidated Statements of Cash Flows (Unaudited)

	For the nine months ended	
	September 30, 2019	September 30, 2018
Cash Flows From Operating Activities:		
Net income (loss)	\$ (1,762,091)	\$ 670,222
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:		
Depreciation and amortization expense	732,702	678,010
Gain on tax settlement	-	(443,110)
Gain on plant acquisition	-	(1,500,000)
Amortization of loan discount	54,110	63,360
Accretion of asset retirement obligation	4,611	4,611
Common stock issued for services	136,000	-
Common stock payable for director fees	96,875	131,250
Foreign exchange (gain) loss	-	-
Other non-cash items	(598)	(681)
Change in:		
Accounts receivable, net	115,451	(211,637)
Inventories	47,187	197,813
Other current assets	-	4,697
IVA receivable and other assets	39,501	(91,592)
Accounts payable	134,237	28,619
Accrued payroll, taxes and interest	41,325	(49,984)
Deferred revenues	-	(27,649)
Other accrued liabilities	47,465	161,486
Payables to related parties	29,683	33,669
Net cash provided (used) by operating activities	<u>(283,542)</u>	<u>(350,916)</u>
Cash Flows From Investing Activities:		
Purchase of properties, plants and equipment	(677,837)	(411,571)
Payment received on note receivable for sale of land	400,000	-
Proceeds from plant acquisition	-	1,500,000
Net cash provided (used) by investing activities	<u>(277,837)</u>	<u>1,088,429</u>
Cash Flows From Financing Activities:		
Net proceeds from (payments to) factor	42,580	5,168
Checks issued and payable	(14,777)	13,572
Stock issued for cash	431,322	-
Advances from related parties	237,400	125,000
Payments on advances from related party	(17,387)	(125,000)
Advances from notes payable to bank	14,311	(92,565)
Principal payments on long-term debt	(116,961)	(178,504)
Net cash provided (used) by financing activities	<u>576,488</u>	<u>(252,329)</u>
NET INCREASE IN CASH AND CASH EQUIVALENTS	15,109	485,184
Cash and cash equivalents and restricted cash at beginning of period	113,897	91,332
Cash and cash equivalents and restricted cash at end of period	<u>\$ 129,006</u>	<u>\$ 576,516</u>
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:		
Noncash investing and financing activities:		
Common stock payable issued to directors	\$ 175,000	\$ 175,000

The accompanying notes are an integral part of the consolidated financial statements.

United States Antimony Corporation and Subsidiaries
Consolidated Statement of Changes in Stockholders' Equity (Unaudited)

For the three month periods ended September 30, 2019 and September 30, 2018

	<u>Total Preferred Stock</u>		<u>Common Stock</u>		<u>Additional Paid In Capital</u>	<u>Accumulated Deficit</u>	<u>Total Stockholders' Equity</u>
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>			
Three months ended September 30, 2019							
Balances, July 1, 2019	2,678,909	\$ 26,788	68,757,354	\$ 687,573	\$36,712,572	\$(26,884,598)	\$10,542,335
Issuance of common stock for cash			904,082	9,041	422,281		431,322
Net loss						(568,592)	(568,592)
Balances, September 30, 2019	<u>2,678,909</u>	<u>\$ 26,788</u>	<u>69,661,436</u>	<u>\$ 696,614</u>	<u>\$37,134,853</u>	<u>\$(27,453,190)</u>	<u>\$10,405,065</u>

	<u>Total Preferred Stock</u>		<u>Common Stock</u>		<u>Additional Paid In Capital</u>	<u>Accumulated Deficit</u>	<u>Total Stockholders' Equity</u>
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>			
Three months ended September 30, 2018							
Balances, July 1, 2018	2,678,909	\$ 26,788	68,227,171	\$ 682,271	\$36,406,874	\$(27,161,549)	\$ 9,954,384
Net income						1,267,447	1,267,447
Balances, September 30, 2018	<u>2,678,909</u>	<u>\$ 26,788</u>	<u>68,227,171</u>	<u>\$ 682,271</u>	<u>\$36,406,874</u>	<u>\$(25,894,102)</u>	<u>\$11,221,831</u>

For the nine month periods ended September 30, 2019 and September 30, 2018

	<u>Total Preferred Stock</u>		<u>Common Stock</u>		<u>Additional Paid In Capital</u>	<u>Accumulated Deficit</u>	<u>Total Stockholders' Equity</u>
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>			
Nine months ended September 30, 2019							
Balances, January 1, 2019	2,678,909	\$ 26,788	68,227,171	\$ 682,271	\$36,406,874	\$(25,691,099)	\$11,424,834
Issuance of common stock to chief financial officer			200,000	2,000	134,000		136,000
Issuance of common stock to Directors			330,183	3,302	171,698		175,000
Issuance of common stock for cash			904,082	9,041	422,281		431,322
Net loss						(1,762,091)	(1,762,091)
Balances, September 30, 2019	<u>2,678,909</u>	<u>\$ 26,788</u>	<u>69,661,436</u>	<u>\$ 696,614</u>	<u>\$37,134,853</u>	<u>\$(27,453,190)</u>	<u>\$10,405,065</u>

	<u>Total Preferred Stock</u>		<u>Common Stock</u>		<u>Additional Paid In Capital</u>	<u>Accumulated Deficit</u>	<u>Stockholders' Equity</u>
	<u>Shares</u>	<u>Amount</u>	<u>Shares</u>	<u>Amount</u>			
Nine months ended September 30, 2018							
Balances, January 1, 2018	2,678,909	\$ 26,788	67,488,153	\$ 674,881	\$36,239,264	\$(26,564,324)	\$10,376,609
Issuance of common stock to Directors			739,018	7,390	167,610		175,000
Net income						670,222	670,222
Balances, September 30, 2018	<u>2,678,909</u>	<u>\$ 26,788</u>	<u>68,227,171</u>	<u>\$ 682,271</u>	<u>\$36,406,874</u>	<u>\$(25,894,102)</u>	<u>\$11,221,831</u>

The accompanying notes are an integral part of the consolidated financial statements.

PART I - FINANCIAL INFORMATION, CONTINUED:

United States Antimony Corporation and Subsidiaries Notes to Consolidated Financial Statements (Unaudited)

1. Basis of Presentation

The unaudited consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial information, as well as the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of the Company's management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation of the interim financial statements have been included. Operating results for the three and nine month periods ended September 30, 2019 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2019.

For further information refer to the financial statements and footnotes thereto in the Company's Annual Report on Form 10-K for the year ended December 31, 2018.

Going Concern Consideration

At September 30, 2019, the Company's consolidated financial statements show negative working capital of approximately \$2.8 million and accumulated deficit of approximately \$27.5 million. In addition, the Company has a net loss of \$1,762,091 and cash used in operations of \$283,542 for the nine-month period ended September 30, 2019. The Company has had recurring operating losses for most of the prior periods. These factors indicate that there is substantial doubt regarding the ability to continue as a going concern for the next twelve months.

The continuing losses are principally a result of the falling prices of antimony and production costs incurred in Mexico.

Antimony prices decreased approximately 14% in the first nine months of 2019 compared to the same period in the prior year. For the nine months ended September 30, 2019, the average sale price for antimony was approximately \$3.56 per pound compared to a price of \$4.14 per pound for the nine months ended September 30, 2018. In addition, during 2019, we have endured supply interruptions from our North American supplier and shipments have resumed although at a lower level than years prior to 2018. A new supply agreement negotiated with our North American supplier in 2017 helped us with cash flow from our antimony division in 2018, but the continued decrease in prices for antimony have caused us to negotiate a better supply agreement in 2019 which will help us with our cash flow situation. We negotiated a \$73,469 decrease in our raw material cost with the supplier for the third quarter.

Since 2017, we have continually reduced labor and other operating costs at our Mexico locations which have resulted in a lower overall production cost in Mexico. In June 2019, we reached agreement with our miners in Mexico to further reduce labor costs. In 2019, we completed installation of three of the large rotating furnaces (LRFs) we obtained from the Lanxess transaction. The Company's 2019-2020 plan involves ramping up production at our antimony properties in Mexico utilizing the additional LRFs obtained from Lanxess. As a result, we expect to increase the antimony output from our Mexican properties in 2020. In 2019, we began selling antimony metal directly from Mexico to customers which saves us approximately \$0.38 per pound in processing costs and freight.

On September 16, 2019, we were awarded a grant for \$510,528 to provide the Defense Logistics Agency of the Department of Defense with six samples of antimony tri-sulfide for testing to determine the consistency for making primers for ordnance per military specification MIL-A-159D. We will be paid \$85,088 per sample over the next twelve months.

1. Basis of Presentation, continued:

The portion of the precious metals recovery system at the Madero smelter is complete and the cyanide leach circuit being built at the Puerto Blanco plant is complete except for the assaying and lab equipment which will be tested in the fourth quarter of 2019. We expect to be receiving income from the production of precious metals some time during the first half of 2020.

Over the past several years, the Company has made principal payments on most of its debt from cash generated from operations without the need for additional borrowings or selling shares of its common stock. However, we are delinquent on some debt payments (see Note 9).

On November 14, 2019, we completed a common stock private placement for \$431,322 to complete the precious metals circuit at our Puerto Blanco milling facility and to make cost saving repairs at our Montana smelter.

Management believes that the actions taken to increase production from both antimony and precious metals coupled with a reduction in production costs will enable the Company to meet most of its obligations for the next twelve months. However, due to the uncertainty of the price of antimony and other operating factors, there is the likelihood that some obligations will not be met.

2. Developments in Accounting Pronouncements

Accounting Standards Updates Adopted

In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02 Leases (Topic 842). The update modified the classification criteria and requires lessees to recognize the assets and liabilities on the balance sheet for most leases. The update was effective for fiscal years beginning after December 15, 2018, with early adoption permitted. Adoption of this update as of January 1, 2019 did not have a material impact on the Company's consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-07 Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The update involves simplification of several aspects of accounting for nonemployee share-based payment transactions by expanding the scope of Topic 718 to include nonemployee awards. The update was effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. Adoption of this update as of January 1, 2019 did not have a material impact on the Company's consolidated financial statements.

Accounting Standards Updates to Become Effective in Future Periods

In August 2018, the FASB issued ASU No. 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The update removes, modifies and makes additions to the disclosure requirements on fair value measurements. The update is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. Management is evaluating the impact of this update on the Company's fair value measurement disclosures.

United States Antimony Corporation and Subsidiaries
Notes to Consolidated Financial Statements (Unaudited)

3. Income (Loss) Per Common Share

Basic earnings per share is calculated by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated based on the weighted average number of common shares outstanding during the period plus the effect of potentially dilutive common stock equivalents, including warrants to purchase the Company's common stock and convertible preferred stock.

Included in the calculation of diluted earnings per share for the three and nine-month periods ended September 30, 2018 are 250,000 shares of common stock warrants. For the three and nine months ended September 30, 2019 and 2018, the potentially dilutive common stock equivalents not included in the calculation of diluted earnings per share as their effect would have been anti-dilutive are as follows:

	September 30, 2019	September 30, 2018
Warrants	702,041	-
Convertible preferred stock	1,751,005	1,751,005
Total possible dilution	2,453,046	1,751,005

4. Revenue Recognition

Our products consist of the following:

- Antimony: includes antimony oxide, sodium antimonate, antimony trisulfide, and antimony metal
- Zeolite: includes coarse and fine zeolite crushed in various sizes
- Precious Metals: includes unrefined and refined gold and silver

For our antimony and zeolite products, revenue is recognized upon the completion of the performance obligation which is met when the transaction price can be reasonably estimated and revenue is recognized generally at the time when risk is transferred. We have determined the performance obligation is met and title is transferred either upon shipment from our warehouse locations or upon receipt by the customer as specified in individual sales orders. The performance obligation is met because at that time, 1) legal title is transferred to the customer, 2) the customer has accepted the product and obtained the ability to realize all of the benefits from the product, 3) the customer has the significant risks and rewards of ownership to it, 4) it is very unlikely product will be rejected by the customer upon physical receipt, and 5) we have the right to payment for the product. Shipping costs related to the sales of antimony and zeolite products are recorded to cost of sales as incurred. For zeolite products, royalty expense due a third party by the Company is also recorded to cost of sales upon sale in accordance with terms of underlying royalty agreements.

For sales of precious metals, the performance obligation is met, the transaction price is known, and revenue is recognized at the time of transfer of control of the agreed-upon metal quantities to the customer. Refining and shipping costs related to sales of precious metals are recorded to cost of sales as incurred.

Sales of products for the three and nine month periods ended September 30, 2019 and 2018 were as follows:

	Three Months Ended September 30,		NineMonths Ended September 30,	
	2019	2018	2019	2018
Antimony	\$ 1,080,871	\$ 1,366,540	\$ 4,294,281	\$ 4,540,873
Zeolite	651,563	653,365	2,081,751	2,026,605
Precious metals	55,500	71,820	140,550	213,523
	\$ 1,787,934	\$ 2,091,725	\$ 6,516,582	\$ 6,781,001

United States Antimony Corporation and Subsidiaries
Notes to Consolidated Financial Statements (Unaudited)

4. Revenue Recognition, continued:

The following is sales information by geographic area based on the location of customers for the three and nine-month periods ended September 30, 2019 and 2018:

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2019	2018	2019	2018
United States	\$ 1,570,364	\$ 1,876,218	\$ 5,498,640	\$ 6,151,068
Canada	217,570	215,507	544,350	629,933
Mexico	-	-	473,592	-
	<u>\$ 1,787,934</u>	<u>\$ 2,091,725</u>	<u>\$ 6,516,582</u>	<u>\$ 6,781,001</u>

Sales of products to significant customers were as follows for the three and nine month periods ended September 30, 2019 and 2018:

Sales to Three Largest Customers	For the Three Months Ended		For the Nine Months Ended	
	September 30,	September 30,	September 30,	September 30,
	2019	2018	2019	2018
Axens North America	\$ 128,805	\$ -	\$ -	\$ -
Ampacet Corporation	-	142,414	-	472,674
Mexichem Specialty Compounds Inc.	314,008	587,568	1,373,533	1,985,249
Kohler Corporation	-	471,358	1,028,624	1,122,908
Nyacol Nanotechnologies	374,070	-	778,394	-
	<u>\$ 816,883</u>	<u>\$ 1,201,340</u>	<u>\$ 3,180,551</u>	<u>\$ 3,580,831</u>
% of Total Revenues	46%	57%	49%	53%

Accounts receivable from largest customers were as follows for September 30, 2019 and December 31, 2018:

Accounts Receivable	September 30, 2019	December 31, 2018
DanaMart	\$ -	\$ 143,890
Axens North America Inc.	46,654	34,912
Earth Innovations Inc.	35,584	35,967
Ralco Mix Products	26,080	-
	<u>\$ 108,318</u>	<u>\$ 214,769</u>
% of Total Receivables	34%	49%

Our trade accounts receivable balance related to contracts with customers was \$322,940 at September 30, 2019 and \$438,391 at December 31, 2018. Our products do not involve any warranty agreements and product returns are not typical.

We have determined our contracts do not include a significant financing component. For antimony and zeolite sales contracts, we may factor certain receivables and receive final payment within 30 days of the performance obligation being met. For antimony and zeolite receivables not factored, we typically receive payment within 10 days. For precious metals sales, a provisional payment of 75% is typically received within 45 days of the date the product is delivered to the customer. After an exchange of assays, a final payment is normally received within 90 days of product delivery.

United States Antimony Corporation and Subsidiaries
Notes to Consolidated Financial Statements (Unaudited)

5. Inventories

Inventories at September 30, 2019 and December 31, 2018 consisted primarily of finished antimony products, antimony metal, antimony ore, and finished zeolite products that are stated at the lower of first-in, first-out cost or estimated net realizable value. Finished antimony products, antimony metal and finished zeolite products costs include raw materials, direct labor and processing facility overhead costs and freight. Inventory at September 30, 2019 and December 31, 2018 is as follows:

	September 30, 2019	December 31, 2018
Antimony Metal	\$ 37,346	\$ 8,127
Sodium Antimonate	28,568	-
Antimony Oxide	147,304	255,782
Antimony Concentrates	-	2,214
Antimony Ore	198,492	257,067
Total antimony	411,710	523,190
Zeolite	296,364	232,071
	<u>\$ 708,074</u>	<u>\$ 755,261</u>

6. Accounts Receivable and Due to Factor

The Company factors designated trade receivables pursuant to a factoring agreement with LSQ Funding Group L.C., an unrelated factor (the "Factor"). The agreement specifies that eligible trade receivables are factored with recourse. We submit selected trade receivables to the factor, and receive 83% of the face value of the receivable by wire transfer. The Factor withholds 15% as retainage, and 2% as a servicing fee. Upon payment by the customer, we receive the remainder of the amount due from the factor. The 2% servicing fee is recorded on the consolidated statement of operations in the period of sale to the factor. John Lawrence, CEO, is a personal guarantor of the amount due to Factor.

Trade receivables assigned to the Factor are carried at the original invoice amount less an estimate made for doubtful accounts. Under the terms of the recourse provision, the Company is required to reimburse the Factor, upon demand, for factored receivables that are not paid on time. Accordingly, these receivables are accounted for as a secured financing arrangement and not as a sale of financial assets. The allowance for doubtful accounts (if any) is based on management's regular evaluation of individual customer's receivables and consideration of a customer's financial condition and credit history. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded when received. Interest is not charged on past due accounts.

We present the receivables, net of allowances, as current assets and we present the amount potentially due to the Factor as a secured financing in current liabilities.

Accounts Receivable	September 30, 2019	December 31, 2018
Accounts receivable - non factored	\$ 263,836	\$ 421,867
Accounts receivable - factored with recourse	59,104	16,524
Accounts receivable - net	<u>\$ 322,940</u>	<u>\$ 438,391</u>

United States Antimony Corporation and Subsidiaries
Notes to Consolidated Financial Statements (Unaudited), Continued:

7. Commitments and Contingencies

In June of 2013, the Company entered into a lease to mine antimony ore from concessions located in the Wadley Mining district in Mexico. The lease calls for a term of one year and, as of September 30, 2019, requires payments of \$10,000 plus a tax of \$1,700, per month. The lease is renewable each year with a 15 day notice to the lessor and agreement of terms. The next lease is scheduled for renewal in June 2020.

8. Notes Payable to Bank

At September 30, 2019, and December 31, 2018, the Company had the following notes payable to bank:

	<u>September 30,</u> <u>2019</u>	<u>December 31,</u> <u>2018</u>
Promissory note payable to First Security Bank of Missoula, bearing interest at 3.150%, payable on demand, collateralized by a lien on Certificate of Deposit	\$ 99,999	\$ 83,918
Promissory note payable to First Security Bank of Missoula, bearing interest at 3.150%, payable on demand, collateralized by a lien on Certificate of Deposit	98,229	99,999
Total notes payable to the bank	<u>\$ 198,228</u>	<u>\$ 183,917</u>

These notes are personally guaranteed by John C. Lawrence the Company's Chief Executive Officer and Chairman of the Board of Directors. The maximum amount available for borrowing under each note is \$99,999.

United States Antimony Corporation and Subsidiaries
Notes to Consolidated Financial Statements (Unaudited), Continued:

9. Debt

Long-Term debt at September 30, 2019 and December 31, 2018 is as follows:

	<u>September 30,</u> <u>2019</u>	<u>December 31,</u> <u>2018</u>
Note payable to Zeo Inc., non interest bearing, payable in 11 quarterly installments of \$8,300 with a final payment of \$8,700; maturing December 2022; uncollateralized. (1)	\$ 100,000	\$ 100,000
Note payable to Cat Financial Services, bearing interest at 6%; payable in monthly installments of \$1,300; maturing August 2019; collateralized by equipment.	1,498	14,022
Note payable to Cat Financial Services, bearing interest at 6%; payable in monthly installments of \$778; maturing December 2022; collateralized by equipment.	28,175	34,390
Note payable to De Lage Landen Financial Services, bearing interest at 3.51%; payable in monthly installments of \$655; maturing September 2019; collateralized by equipment.	1,998	5,851
Note payable to De Lage Landen Financial Services, bearing interest at 3.51%; payable in monthly installments of \$655; maturing September 2019; collateralized by equipment.	-	8,371
Note payable to Phyllis Rice, bearing interest at 1%; payable in monthly installments of \$2,000; originally maturing March 2015; collateralized by equipment.	6,146	12,146
Obligation payable for Soyatal Mine, non-interest bearing, annual payments of \$100,000 or \$200,000 through 2020, net of discount of \$19,156 and \$23,321, respectively. (2)	667,243	639,747
Obligation payable for Guadalupe Mine, non-interest bearing, annual payments from \$60,000 to \$149,078 through 2026, net of discount of \$201,527 and \$252,444, respectively. (3)	922,779	918,663
	<u>1,727,839</u>	<u>1,733,190</u>
Less current portion	(851,766)	(705,460)
Long-term portion	<u>\$ 876,073</u>	<u>\$ 1,027,730</u>

(1) Payments starting the fourth quarter of 2019.

(2) At September 30, 2019, the Company has not made \$465,021 of principal payments due in previous periods on this note. At September 30, 2019, all but \$23,585 of the balance is classified as a current liability. The creditor has agreed to accept payments of \$2,500 per month through June 30, 2020, at which time the parties may agree to an extension of that payment schedule, or modify the payment schedule. The note holder accepted, and was paid, \$40,000 during the nine months ended September 30, 2019.

(3) At September 30, 2019, the Company is delinquent in \$91,578 of principal payments on this note. At September 30, 2019, the delinquent balance is classified as a current liability. The Company is currently working with the lenders to modify the payment terms to cure the delinquent status. The Company has not received notice from the lenders indicating default on the loan.

United States Antimony Corporation and Subsidiaries
Notes to Consolidated Financial Statements (Unaudited), Continued:

9. Debt, continued:

At September 30, 2019, principal payments on debt are due as follows:

	12 Months Ending September 30,	Principal Payment	Discount	Net
	2020	\$ 910,048	\$ (58,282)	\$ 851,766
	2021	223,957	(45,335)	178,622
	2022	191,052	(37,610)	153,442
	2023	177,716	(30,922)	146,794
	2024	149,077	(23,833)	125,244
	Thereafter	296,642	(24,671)	271,971
		<u>\$ 1,948,492</u>	<u>\$ (220,653)</u>	<u>\$ 1,727,839</u>

10. Related Party Transactions

During the three and nine months ended September 30, 2018, the Chairman of the audit committee and compensation committee received \$4,500 for services performed. No compensation was paid during the three and nine month periods ended September 30, 2019. See Note 12 for shares of common stock issued to directors.

For the three and nine months ended September 30, 2019, the Company paid \$1,764 and \$8,034, respectively, compared to \$1,764, and \$6,686 for the three and nine months ended June 30, 2018, to John Lawrence, our President and Chief Executive Officer, as reimbursement for equipment used by the Company. Mr. Lawrence advanced the Company \$227,200 for ongoing operating expenses during the nine months ended September 30, 2019, of which \$17,387 has been repaid. In addition to the loan that was owed to Mr. Lawrence at September 30, 2019, the Company also owed Mr. Lawrence for payroll and other liabilities equal to \$123,250 for a total owed to Mr. Lawrence at September 30, 2019 of \$333,063.

John Gustaven, executive Vice President of the Company, advanced the Company \$10,200 during the quarter ended September 30, 2019, and is included in payables to related parties at September 30, 2019.

11. Income Taxes

During the three and nine months ended September 30, 2019, and the year ended December 31, 2018, the Company determined that a valuation allowance equal to 100% of any deferred tax asset was appropriate, as management of the Company cannot determine that it is more likely than not the Company will realize the benefit of its net deferred tax asset. The net effect is that the deferred tax asset is fully reserved for at September 30, 2019 and December 31, 2018. Management estimates the effective tax rate at 0% for the current year.

Mexican Tax Assessment

In 2015, the Mexican tax authority ("SAT") initiated an audit of the USAMSA's 2013 income tax return. In October 2016, as a result of its audit, SAT assessed the Company \$13.8 million pesos, which was approximately \$666,400 in U.S. Dollars ("USD") as of December 31, 2016. Approximately \$285,000 USD of the total assessment is interest and penalties. SAT's assessment is based on the disallowance of specific costs that the Company deducted on the 2013 USAMSA income tax return. These disallowed costs were incurred by the Company for USAMSA's business operations.

Management reviewed the assessment notice from SAT and believed numerous findings have no merit. The Company engaged accountants and tax attorneys in Mexico to defend its position. An appeal was filed.

11. Income Taxes, continued:

As of December 31, 2017, the Company had accrued a potential tax liability of \$443,110 associated with this assessment. In the third quarter of 2018, we settled a tax assessment from the Mexican government completely in our favor. The accrual of \$443,110 recorded as potential tax liability was reversed and recognized as a gain during the quarter ended September 30, 2018. The Company paid Mexican tax representatives \$157,500 that were recognized as professional fees expense, to negotiate this settlement during the quarter ended September 30, 2018.

The Company has been notified that SAT has re-opened its assessment of USAMSA's 2013 income tax return which could result in a separate assessment. It is too early in the process to estimate any potential outcome. At September 30, 2019, the Company does not believe it will be assessed any taxes, interest or penalties as a result of this assessment.

12. Stockholder's Equity

Issuance of Common Stock for Payable to Board of Directors

During the nine-month period ended September 30, 2019, the Board of Directors was issued a total of 330,183 shares of common stock for \$175,000 in directors' fees that were payable at December 31, 2018. In addition, during the three and nine months ended September 30, 2019, the Company accrued \$34,375 and \$96,875, respectively, in directors' fees payable that will be paid in common stock.

In January 2019, the Company issued Daniel Parks, the Company's Chief Financial Officer, 200,000 shares of the Company's common stock with a fair value of \$136,000 to retain his services. As part of the agreement, Mr. Parks' hours worked and cash compensation were reduced.

On May 3, 2018, the Board of Directors was issued a total of 739,018 shares of common stock for \$175,000 in directors' fees that were payable at December 31, 2017. In addition, during the three and nine months ended September 30, 2018, the Company accrued \$43,750 and \$131,250, respectively, in directors' fees payable that will be paid in common stock.

Issuance of Common Stock for Cash

During the nine-month period ended September 30, 2019, the Company sold 904,082 shares of its common stock for \$0.48 per share for proceeds of \$431,322. Included with each share was a common stock warrant to purchase 1/2 share (total of 452,041) of the Company's common stock exercisable at \$0.65. The warrants expire in 2022.

13. Plant Acquisition

On August 31, 2018, the Company closed a Member Interest and Capital Share Agreement (the "Agreement") with Great Lakes Chemical Corporation and Lanxess Holding Company US Inc., as the sellers, and the Company as the buyer. Under the Agreement, the Company acquired a subsidiary of the sellers which includes an antimony plant, equipment and land located in Reynosa, Mexico. The Company disassembled, salvaged, and transported the antimony plant and equipment for use in its existing operations in both Mexico and the United States. The project involved moving heavy equipment and was completed in the second quarter of 2019. In addition, the Company was paid \$1,500,000 by the sellers, which was recognized as operating income in the quarter ended September 30, 2018, to assist in the salvage and transport costs of the useable equipment. The transaction was accounted for as an asset acquisition as there was no business associated with the acquired assets. The real property acquired with the plant was sold for \$700,000 in November 2018, for which the Company received \$300,000 in 2018 and the remaining balance of \$400,000 in the three month period ended March 31, 2019.

United States Antimony Corporation and Subsidiaries
Notes to Consolidated Financial Statements (Unaudited), Continued:

14. Business Segments

The Company is currently organized and managed by four segments, which represent our operating units: United States antimony operations, Mexican antimony operations, precious metals recovery and United States zeolite operations.

The Madero smelter and Puerto Blanco mill at the Company's Mexico operation produces crude oxide and crude metal that is shipped to Montana for finishing at the Thompson Falls, Montana, plant, or finished antimony metal that is sold directly to customers in the United States. The precious metals recovery plant is operated in conjunction with the antimony processing plant at Thompson Falls, Montana. The zeolite operation produces zeolite near Preston, Idaho. Almost all of the sales of products from the United States antimony and zeolite operations are to customers in the United States.

Segment disclosure regarding sales to major customers is located in Note 4.

Total Assets:	<u>September 30, 2019</u>	<u>December 31, 2018</u>
Antimony		
United States	\$ 2,062,312	\$ 2,199,694
Mexico	12,412,737	12,824,292
Subtotal Antimony	<u>14,475,049</u>	<u>15,023,986</u>
Precious metals	581,314	615,719
Zeolite	1,916,963	1,917,418
Total	<u>\$ 16,973,326</u>	<u>\$ 17,557,123</u>

Capital expenditures:	<u>For the Three Months Ended</u>		<u>For the Nine Months Ended</u>	
	<u>September 30, 2019</u>	<u>September 30, 2018</u>	<u>September 30, 2019</u>	<u>September 30, 2018</u>
Antimony				
United States	\$ -	\$ -	\$ 2,713	\$ -
Mexico	190,861	223,390	607,564	334,367
Subtotal Antimony	<u>190,861</u>	<u>223,390</u>	<u>610,277</u>	<u>334,367</u>
Precious Metals	4,095	-	17,247	40,988
Zeolite	9,304	13,793	50,313	36,216
Total	<u>\$ 204,260</u>	<u>\$ 237,183</u>	<u>\$ 677,837</u>	<u>\$ 411,571</u>

United States Antimony Corporation and Subsidiaries
Notes to Consolidated Financial Statements (Unaudited), Continued:

14. Business Segments, continued:

Segment Operations for the three months ended September 30, 2019	Antimony USA	Antimony Mexico	Total Antimony	Precious Metals	Zeolite	Totals
Total revenues	\$ 1,080,871	\$ -	\$ 1,080,871	\$ 55,500	\$ 651,563	\$ 1,787,934
Depreciation and amortization	\$ 10,935	\$ 210,766	\$ 221,701	\$ 17,630	\$ 46,825	\$ 286,156
Income (loss) from operations	227,712	(921,965)	(694,253)	37,869	114,923	(541,461)
Other income (expense):	(4,602)	(18,037)	(22,639)	-	(4,492)	(27,131)
NET INCOME (LOSS)	\$ 223,110	\$ (940,002)	\$ (716,892)	\$ 37,869	\$ 110,431	\$ (568,592)
Segment Operations for the three months ended September 30, 2018	Antimony USA	Antimony Mexico	Total Antimony	Precious Metals	Zeolite	Totals
Total revenues	\$ 1,366,540	\$ -	\$ 1,366,540	\$ 71,820	\$ 653,365	\$ 2,091,725
Depreciation and amortization	\$ 13,170	\$ 148,363	\$ 161,533	\$ 17,011	\$ 46,807	\$ 225,351
Income (loss) from operations	1,259,735	(537,067)	722,668	54,809	88,263	865,740
Other income (expense):	(3,715)	409,238	405,523	-	(3,816)	401,707
NET INCOME (LOSS)	\$ 1,256,020	\$ (127,829)	\$ 1,128,191	\$ 54,809	\$ 84,447	\$ 1,267,447

United States Antimony Corporation and Subsidiaries
Notes to Consolidated Financial Statements (Unaudited), Continued:

14. Business Segments, continued:

Segment Operations for the nine months ended September 30, 2019	Antimony USA	Antimony Mexico	Total Antimony	Precious Metals	Zeolite	Totals
Total revenues	\$ 3,820,689	\$ 473,592	\$ 4,294,281	\$ 140,550	\$ 2,081,751	\$ 6,516,582
Depreciation and amortization	\$ 32,690	\$ 508,934	\$ 541,624	\$ 51,652	\$ 139,426	\$ 732,702
Income (loss) from operations	1,083,360	(3,318,053)	(2,234,693)	88,898	460,149	(1,685,646)
Other income (expense):	(10,388)	(54,375)	(64,763)	-	(11,682)	(76,445)
NET INCOME (LOSS)	\$ 1,072,972	\$ (3,372,428)	\$ (2,299,456)	\$ 88,898	\$ 448,467	\$ (1,762,091)
Segment Operations for the nine months ended September 30, 2018	Antimony USA	Antimony Mexico	Total Antimony	Precious Metals	Zeolite	Totals
Total revenues	\$ 4,540,873	\$ -	\$ 4,540,873	\$ 213,523	\$ 2,026,605	\$ 6,781,001
Depreciation and amortization	\$ 39,550	\$ 445,729	\$ 485,279	\$ 51,032	\$ 141,699	\$ 678,010
Income (loss) from operations	1,849,669	(2,088,424)	(238,755)	162,491	382,182	305,918
Other income (expense):	(6,431)	379,750	373,319	-	(9,015)	364,304
NET INCOME (LOSS)	\$ 1,843,238	\$ (1,708,674)	\$ 134,564	\$ 162,491	\$ 373,167	\$ 670,222

ITEM 2. Management's Discussion and Analysis of Results of Operations and Financial Condition
General

Certain matters discussed are forward-looking statements that involve risks and uncertainties, including the impact of antimony prices and production volatility, changing market conditions and the regulatory environment and other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of this filing. We disclaim, however, any intent or obligation to update these forward-looking statements.

	Three Months Ended September 30, 2019	Three Months Ended September 30, 2018	Nine Months Ended September 30, 2019	Nine Months Ended September 30, 2018
Antimony - Combined USA				
and Mexico				
Lbs of Antimony Metal USA	187,889	229,865	597,308	690,838
Lbs of Antimony Metal Mexico	155,549	105,748	607,407	405,329
Total Lbs of Antimony Metal Sold	343,438	335,613	1,204,715	1,096,167
Average Sales Price/Lb Metal	\$ 3.15	\$ 4.07	\$ 3.56	\$ 4.14
Net income (loss)/Lb Metal	\$ (2.09)	\$ 3.36	\$ (1.91)	\$ 0.12
Gross antimony revenue	\$ 1,080,871	\$ 1,366,540	\$ 4,294,281	\$ 4,540,873
Cost of sales - USA	(628,050)	(735,284)	(2,271,512)	(2,759,947)
Cost of sales - Mexico	(892,714)	(973,149)	(3,138,309)	(2,484,242)
Operating income (expenses)	(254,360)	1,064,561	(1,119,153)	464,561
Non-operating income (expenses)	(22,639)	405,523	(64,763)	373,319
	<u>(1,797,763)</u>	<u>(238,349)</u>	<u>(6,593,737)</u>	<u>(4,406,310)</u>
Net income (loss) - antimony	(716,892)	1,128,191	(2,299,456)	134,564
Depreciation, & amortization	221,701	161,533	541,624	485,279
EBITDA - antimony	\$ (495,191)	\$ 1,289,724	\$ (1,757,832)	\$ 619,843
Precious Metals				
Ounces sold				
Gold	12	24	36	54
Silver	3,445	5,415	8,333	15,256
Gross precious metals revenue	\$ 55,500	\$ 71,820	\$ 140,550	\$ 213,523
Cost of sales	(17,631)	(17,011)	(51,652)	(51,032)
Net income - precious metals	37,869	54,809	88,898	162,491
Depreciation	17,630	17,011	51,652	51,032
EBITDA - precious metals	\$ 55,499	\$ 71,820	\$ 140,550	\$ 213,523
Zeolite				
Tons sold				
	3,483	3,556	10,924	10,887
Average Sales Price/Ton	\$ 187.07	\$ 183.74	\$ 190.57	\$ 186.15
Net income (loss)/Ton	\$ 31.71	\$ 23.75	\$ 41.05	\$ 34.28
Gross zeolite revenue	\$ 651,563	\$ 653,365	\$ 2,081,751	\$ 2,026,605
Cost of sales	(520,356)	(543,410)	(1,568,174)	(1,576,649)
Operating income (expenses)	(16,284)	(21,692)	(53,428)	(67,774)
Non-operating income (expenses)	(4,492)	(3,816)	(11,682)	(9,015)
Net income - zeolite	110,431	84,447	448,467	373,167
Depreciation	46,825	46,807	139,426	141,699
EBITDA - zeolite	\$ 157,256	\$ 131,254	\$ 587,893	\$ 514,866
Company-wide				
Gross revenue	\$ 1,787,934	\$ 2,091,725	\$ 6,516,582	\$ 6,781,001
Cost of sales	(2,058,751)	(2,268,854)	(7,029,647)	(6,871,870)
Operating expenses	(270,644)	1,042,869	(1,172,581)	396,787
Non-operating expenses	(27,131)	401,707	(76,445)	364,304
Net income (loss)	(568,592)	1,267,447	(1,762,091)	670,222
Depreciation, & amortization	286,156	225,351	732,702	678,010
EBITDA	\$ (282,436)	\$ 1,492,798	\$ (1,029,389)	\$ 1,348,232

PART I - FINANCIAL INFORMATION, CONTINUED:

ITEM 2. Management's Discussion and Analysis of Results of Operations and Financial Condition, continued:

Company-Wide

For the third quarter of 2019, we recognized a net loss of \$568,592 on sales of \$1,787,934, after depreciation and amortization of \$286,156. We reported a net income of \$1,267,447 in the third quarter of 2018 on sales of \$2,091,725, after depreciation and amortization of \$225,351. In the third quarter of 2018, the profit was due to a transaction where we acquired a company, Lanxess Laurel, and were paid \$1,500,000 to dismantle and dispose of the acquired company's assets.

For the first nine months of 2019, we recognized a net loss of \$1,762,091, on sales of \$6,516,582, after depreciation and amortization of \$732,702. For the first nine months of 2018, we reported a net income of \$670,222 on sales of \$6,781,001, after depreciation and amortization of \$678,010. The profit for the nine months ending September 30, 2018, was due to the Lanxess Laurel transaction.

For the three and nine months ended September 30, 2019, EBITDA was (\$282,436) and (\$1,029,389), compared to an EBITDA of \$1,492,798 and \$1,348,232 for the same periods of 2018. The positive EBITDA for the three and nine months ending September 30, 2018, was due to the Lanxess Laurel transaction.

Net non-cash expense items totaled \$347,943 for the three months ended September 30, 2019 and included \$286,156 for depreciation and amortization, \$18,037 for amortization of debt discount, and \$43,750 for director compensation. Net non-cash expense items totaled \$1,019,687 for the nine months ended September 30, 2019 and included \$732,702 for depreciation and amortization, \$54,110 of debt discount, \$136,000 for common stock issued for services, and \$96,875 for director compensation.

Net non-cash expense items totaled \$302,973 for the three months ended September 30, 2018 and included \$225,351 for depreciation and amortization, \$21,120 for amortization of debt discount, \$43,750 for director compensation and \$12,752 for other items. Net non-cash expense items totaled \$872,620 for the nine months ended September 30, 2018 and included \$678,010 for depreciation and amortization, \$63,360 of debt discount, \$131,250 for director compensation.

For the three and nine months ended September 30, 2019, general and administrative expenses were \$139,456 and \$498,539, respectively, compared to \$151,825 and \$489,067 for the same periods in 2018.

The falling price for antimony was the primary reason for the increases in our year-over-year losses. Also, in the first half of 2019, we were involved in dismantling furnaces and equipment at Reynosa, Mexico, and moving it to our other operations in Mexico. We also spent time and money preparing our Los Juarez precious metals project for operation and installing furnaces at the Madero smelter. These projects negatively affected our profits.

Antimony

For the three and nine months ended September 30, 2019, we sold 343,438 and 1,204,715 pounds of antimony compared to 335,613 and 1,096,167 pounds for the three and nine months ended September 30, 2018. The increase in sales volume was 2.3% and 9.9% for the three and nine months ending September 30, 2019, respectively. We had an increase in raw material from Mexico of approximately 49,000 pounds for the third quarter of 2019, and an increase of approximately 202,000 pounds for the nine months ended September 30, 2019, compared to the same periods from a year ago.

The average sales price of antimony during the three and nine months ended September 30, 2019 was \$3.15 and \$3.56 per pound compared to \$4.07 and \$4.14 during the same periods in 2018. This was a decrease of 22.6% for the third quarter of 2019, and 14.0% for the nine months ending September 30, 2019, compared to the same periods from a year ago.

As of September 30, 2019, we have installed three of the large rotating furnaces (LRF) we acquired from the Lanxess Reynosa plant at our Madero smelter. These furnaces are lined and are more efficient than our old LRF, and they will increase our production and efficiency, which will cut our production costs substantially.

To further cut costs, we are producing antimony metal in Mexico, and we are renegotiating our raw material cost both in Mexico and from our North American supplier.

Precious Metals

The cyanide leach circuit at Puerto Blanco has been permitted, and construction of the leach circuit is nearly complete, and we expect to start pilot production during the fourth quarter of 2019. The largest project was the construction of the tailings pond, and it is ready for production to start. We need to complete the installation of lab and assay equipment, calibrate the equipment, and train employees in the use of the equipment.

For the three and nine months ended September 30, 2019, EBITDA for precious metals was \$55,499 and \$140,550, compared to \$71,820 and \$213,523 for the same periods of 2018.

We estimate the future recovery of precious metals per metric ton, after the caustic leach and cyanide leach circuits, is as follows:

Schedule of recovery values	Metal	Assay	Recovery	Value	Value/Mt
	Gold	0.035 opmt	90%	\$1500/oz	\$47.25
	Silver	3.27 opmt	85%	\$18.0/oz	\$50.03
	Antimony	0.652%	75%	3.15/lb	\$33.85
	Total				\$131.13

Current and prior periods' revenue from precious metals is as follows:

Precious Metal Sales Silver/Gold	For the three months ended September 30,		For the nine months ended September 30,	
	2019	2018	2019	2018
Montana				
Ounces Gold Shipped (Au)	12.53	24.26	27.67	53.69
Ounces Silver Shipped (Ag)	3,444.68	5,415.00	7,604.84	15,256.00
Total Revenues	\$ 55,500	\$ 71,820	\$ 117,979	\$ 213,523
Mexico				
Ounces Gold Shipped (Au)	-	-	8.21	-
Ounces Silver Shipped (Ag)	-	-	727.88	-
Total Revenues	-	-	\$ 22,571	-

Bear River Zeolite (BRZ)

For the three and nine months ended September 30, 2019, BRZ sold 3,483 and 10,924 tons of zeolite compared to 3,556 and 10,887 tons in the same periods of 2018, a decrease of 73 tons for the three months and an increase of 37 tons for the nine months.

BRZ realized net income of \$110,431 in the third quarter of 2019, compared to \$84,447 in the third quarter of 2018. For the nine months ended September 30, 2019, BRZ realized net income of \$448,467 compared to a net income of \$373,167 for the same period a year ago.

BRZ realized an EBITDA for the three and nine months ended September 30, 2019 of \$157,256 and \$587,893, compared to \$131,254 and \$514,866 for the same periods in 2018.

We are anticipating continued growth in all areas of zeolite sales due to new customers and increasing demand from existing customers as customers realize that BRZ zeolite is one of the finest clinoptilolite zeolites in the world.

Financial Position

Financial Condition and Liquidity

	September 30, 2019	December 31, 2018
Current assets	\$ 1,356,324	\$ 1,903,256
Current liabilities	(4,178,761)	(3,517,618)
Net Working Capital	<u>\$ (2,822,437)</u>	<u>\$ (1,614,362)</u>

	Nine Months Ended	
	September 30, 2019	September 30, 2018
Cash provided (used) by operations	\$ (283,542)	\$ (350,916)
Cash used for capital outlay	(677,837)	(411,571)
Proceeds from plant acquisition	-	1,500,000
Payment received on note receivable for sale of land	400,000	-
Cash provided (used) by financing:		
Net proceeds (payments to) factor	42,580	5,168
Proceeds from notes payable to bank	14,311	-
Change in checks issued and payable	(14,777)	13,572
Advances from related party	237,400	125,000
Payment on advances from related party	(17,387)	(125,000)
Payment of notes payable to bank	-	(92,565)
Stock issued for cash	431,322	-
Principal paid on long-term debt	(116,961)	(178,504)
Net change in cash and cash equivalents	<u>\$ 15,109</u>	<u>\$ 485,184</u>

At September 30, 2019, the Company's consolidated financial statements show negative working capital of approximately \$2.8 million and accumulated deficit of approximately \$27.5 million. In addition, the Company has a net loss of \$1,762,091 and cash used in operations of \$283,542 for the nine-month period ended September 30, 2019. The Company has had recurring operating losses for most of the prior periods. These factors indicate that there is substantial doubt regarding the ability to continue as a going concern for the next twelve months.

The continuing losses are principally a result of the falling prices of antimony and production costs incurred in Mexico.

Antimony prices decreased approximately 14% in the first nine months of 2019 compared to the same period in the prior year. For the nine months ended September 30, 2019, the average sale price for antimony was approximately \$3.56 per pound compared to a price of \$4.14 per pound for the nine months ended September 30, 2018. In addition, during 2019, we have endured supply interruptions from our North American supplier and shipments have resumed although at a lower level than years prior to 2018. A new supply agreement negotiated with our North American supplier in 2017 helped us with cash flow from our antimony division in 2018, but the continued decrease in prices for antimony have caused us to negotiate a better supply agreement in 2019 which will help us with our cash flow situation. We negotiated a \$73,469 decrease in our raw material cost with the supplier for the third quarter.

Since 2017, we have continually reduced labor and other operating costs at our Mexico locations which have resulted in a lower overall production cost in Mexico. In June 2019, we reached agreement with our miners in Mexico to further reduce labor costs. In 2019, we completed installation of three of the large rotating furnaces (LRFs) we obtained from the Lanxess transaction. The Company's 2019-2020 plan involves ramping up production at our antimony properties in Mexico utilizing the additional LRFs obtained from Lanxess. As a result, we expect to increase the antimony output from our Mexican properties in 2020. In 2019, we began selling antimony metal directly from Mexico to customers which saves us approximately \$0.38 per pound in processing costs and freight.

On September 16, 2019, we were awarded a grant for \$510,528 to provide the Defense Logistics Agency of the Department of Defense with six samples of antimony tri-sulfide for testing to determine the consistency for making primers for ordnance per military specification MIL-A-159D. We will be paid \$85,088 per sample over the next twelve months.

The portion of the precious metals recovery system at the Madero smelter is complete and the cyanide leach circuit being built at the Puerto Blanco plant is complete except for the assaying and lab equipment which will be tested in the fourth quarter of 2019. We expect to be receiving income from the production of precious metals some time during the first half of 2020.

Over the past several years, the Company has made principal payments on most of its debt from cash generated from operations without the need for additional borrowings or selling shares of its common stock. However, we are delinquent on some debt payments (see Note 9).

On November 14, 2019, we completed a common stock private placement for \$431,322 to complete the precious metals circuit at our Puerto Blanco milling facility and to make cost saving repairs at our Montana smelter.

Management believes that the actions taken to increase production from both antimony and precious metals coupled with a reduction in production costs will enable the Company to meet most of its obligations for the next twelve months. However, due to the uncertainty of the price of antimony and other operating factors, there is a likelihood that some obligations will not be met.

ITEM 3.

None

ITEM 4. Controls and Procedures**EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES**

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to management, as appropriate, to allow timely decisions regarding required disclosure. Our chief financial officer conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) and 15d-15(e)) as of September 30, 2019. It was determined that there were material weaknesses affecting our disclosure controls and procedures and, as a result of those weaknesses, our disclosure controls and procedures were not effective as of September 30, 2019. These material weaknesses are as follows:

- Inadequate design of internal control over the preparation of the financial statements and financial reporting processes;
- Inadequate monitoring of internal controls over significant accounts and processes including controls associated with domestic and Mexican subsidiary operations and the period-end financial reporting process; and
- The absence of proper segregation of duties within significant processes and ineffective controls over management oversight, including antifraud programs and controls.

We are aware of these material weaknesses and will develop procedures to ensure that independent review of material transactions is performed. The chief financial officer will develop internal control measures to mitigate the lack of inadequate documentation of controls and the monitoring of internal controls over significant accounts and processes including controls associated with the period-ending reporting processes, and to mitigate the segregation of duties within significant accounts and processes and the absence of controls over management oversight, including antifraud programs and controls.

We plan to consult with independent experts when complex transactions are entered into.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There were no significant changes made to internal controls over financial reporting for the quarter ended September 30, 2019 .

PART II - OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

None

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

Item 3. DEFAULTS UPON SENIOR SECURITIES

The registrant has no outstanding senior securities.

Item 4. MINE SAFETY DISCLOSURES

The information concerning mine safety violations or other regulatory matters required by Section 1503 (a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 104 of Regulation S-K is included in Exhibit 95 to this Annual Report.

Item 5. OTHER INFORMATION

None

Item 6. EXHIBITS AND REPORTS ON FORM 8-K

Certifications

Certifications Pursuant to the Sarbanes-Oxley Act

Reports on Form 8-K None

SIGNATURES

Pursuant to the requirements of Section 13 or 15(b) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

UNITED STATES ANTIMONY CORPORATION
(Registrant)

/s/ John C. Lawrence

John C. Lawrence

Director and President (Principal Executive)

Date: November 14, 2019

/s/ Daniel L. Parks

Daniel L. Parks

Chief Financial Officer

Date: November 14, 2019

CERTIFICATIONS

I, John C. Lawrence, President and Chief Executive Officer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of United States Antimony Corporation.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. I have disclosed, based on my most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ John C. Lawrence

John C. Lawrence

President and Chief Executive Officer

Date: November 14, 2019

CERTIFICATIONS

I, Daniel L. Parks, Chief Financial Officer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of United States Antimony Corporation.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. I have disclosed, based on my most recent evaluation, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Daniel L. Parks
Daniel L. Parks
Chief Financial Officer

Date: November 14, 2019

CERTIFICATION PURSUANT TO THE SARBANES-OXLEY ACT
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

I, John C. Lawrence, President, and Chief Executive Officer of United States Antimony Corporation (the "Company") do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

This Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2019, as filed with the Securities and Exchange Commission (the "report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ John C. Lawrence

John C. Lawrence

President and Chief Executive Officer

Date: November 14, 2019

CERTIFICATION PURSUANT TO THE SARBANES-OXLEY ACT
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

I, Daniel L. Parks, Chief Financial Officer of United States Antimony Corporation (the "Company") do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

This Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2019, as filed with the Securities and Exchange Commission (the "report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Daniel L. Parks
Daniel L. Parks
Chief Financial Officer

Date: November 14, 2019



UNITED STATES ANTIMONY CORPORATION
 POST OFFICE BOX 643
 THOMPSON FALLS, MONTANA 59873-0643
 406-827-3523
 406-827-3543 FAX
 tff13543@blackfoot.net E-MAIL

Exhibit 95 MINE SAFETY DISCLOSURES

Pursuant to Section 1503(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act"), issuers that are operators, or that have a subsidiary that is an operator, of a coal or other mine in the United States are required to disclose in their periodic reports filed with the SEC information regarding specified health and safety violations, orders and citations, related assessments and legal actions, and mining-related fatalities. During the quarter ended September 30, 2019, the Company had the following specified health and safety violations, orders or citations, related assessments or legal actions, mining-related fatalities, or similar events in relation to the Company's United States operations requiring disclosure pursuant to Section 1503(a) of the Dodd-Frank Act.

Mine	Mine Act §104 Violations (1)	Mine Act §104(b) Orders (2)	Mine Act §104(d) Citations and Orders (3)	Mine Act §(b) (2) Violations (4)	Mine Act §107(a) Orders (5)	Proposed Assessments from MSHA (In dollars\$)	Mining Related Fatalities	Mine Act §104(e) Notice (yes/no) (6)	Pending Legal Action before Federal Mine Safety and Health Review Commission (yes/no)
Bear River Zeolite	0	0	0	0	0	\$ 363	0	No	No